IL17A and arthropathy: Similar results were seen in analyses from the two phase 3 PSUMMIT studies of ustekinumab, which reported that serum levels of IL-23, IL-17A, and IL-17F correlated with baseline skin disease in participants with PsA, but did not find a clear association of these cytokines with joint disease [17].